REGN FY 2022 Earnings — Regeneron Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

REGNRegeneron Pharmaceuticals, Inc.

$81B

FY 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$12.2B-24.3% YoY

Gross Profit

$10.5B86.0% margin

Operating Income

$5.4B44.2% margin

Net Income

$4.3B35.6% margin

EPS (Diluted)

$38.22

Cash Flow

Operating Cash Flow

$5.0B

Free Cash Flow

$4.4B

Stock-Based Comp.

$725M

Balance Sheet

Total Assets

$29.2B

Total Liabilities

$6.6B

Stockholders' Equity

$22.7B

Cash & Equivalents

$3.1B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$12.2B	$16.1B	-24.3%
Gross Profit	$10.5B	$13.3B	-21.6%
Operating Income	$5.4B	$8.9B	-39.8%
Net Income	$4.3B	$8.1B	-46.3%